Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and announces Series A financing extension

▤ Summary

Alchemab Therapeutics started a Phase 1 first-in-human trial for ATLX-1282 and tied the milestone to its earlier licensing deal with Eli Lilly. The company also closed a $32 million Series A extension, bringing total Series A capital to $114 million. Lilly and Ono Venture Investment joined existing investors in the financing. Alchemab will run the initial study while Lilly leads further development and commercialization of the candidate. The new capital will help Alchemab advance ATLX-2847 and other programs into clinical development.

$ Funding

▦ Linked Companies